The state of California currently has 940 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT04913337
Recruiting
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: University of Southern California, Los Angeles, California +2 locations
Conditions: Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
Register for Updates
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
NCT03748186
Recruiting
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit, Los Angeles, California +1 locations
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
NCT03287271
Recruiting
The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer. The study will evaluate whether this regimen is safe. The study will also evaluate whether the regimen can reduce the amount of cancerous cells in your body. If you agree, you will be treated with VS-6063 by mouth, as well as carboplatin and paclitaxel infusions. Carboplatin and paclitaxel are approved by the FDA for the treatment of ovarian cancer. V... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: University of California San Diego, San Diego, California
Conditions: Ovarian Cancer
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Providence Facey Medical Foundation, Mission Hills, California +1 locations
Conditions: Colorectal Cancer
Register for Updates
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT05453825
Recruiting
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: Cohort A: CRC Cohort B: Gastric and GEJ cancer Cohort C: TNBC Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Keck Medicine of USC, Los Angeles, California
Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Register for Updates
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127
Recruiting
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2023
Locations: The Oncology Institute of Hope & Innovation, Anaheim, California +1 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Register for Updates
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT03708224
Recruiting
To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/13/2023
Locations: University of San Francisco, California, San Francisco, California
Conditions: Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT03682289
Recruiting
This phase II trial studies how well Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor AZD6738 works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop the growth... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/14/2022
Locations: University of California, San Francisco, San Francisco, California
Conditions: Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
Register for Updates
[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy
NCT03142204
Recruiting
This is a Phase 1 study is to visualize biodistribution of a PET tracer called [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/01/2022
Locations: UCSF Imaging Center at China Basin, San Francisco, California
Conditions: Cancer
Register for Updates
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
NCT03991741
Recruiting
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is suppressed from attacking these special tumor fighting cells. This is called transfer of autologous (they came from you) tumor infiltrating lymphocytes (the cells that have been grown in the laboratory. Participants getting these cell infusions will also be treated with interleu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2022
Locations: UC San Diego Moores Cancer Center, La Jolla, California
Conditions: Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Register for Updates
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
NCT04290897
Recruiting
This phase II trial studies how well oxaloacetate works in reducing cognitive complaints in stage 0-IIIA breast cancer survivors. Oxaloacetate is a natural substance found in the body and is available as a nutritional supplement. Giving oxaloacetate may reduce inflammation in the brain that could be contributing to cognitive complaints seen after cancer treatments.
Gender:
Female
Ages:
Between 18 years and 74 years
Trial Updated:
12/01/2022
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Register for Updates
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
NCT04152499
Recruiting
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: Triple negative breast cancer Epithelial ovarian cancer Non-small cell lung cancer Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma Small cell lung can... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/29/2022
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Gastric Adenocarcinoma, Breast Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Epithelial Ovarian Cancer, Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates